Cite
HARVARD Citation
de Botton, S. et al. (2021). Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer medicine. pp. 6336-6343. [Online].